GlassScriptPhysician profile
Bhavin R Dave
NPI 1144202300
$11,064.56
in general payments reported to CMS, 2019-2025
23 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,237 · 2020: $923 · 2021: $1,139 · 2022: $494 · 2023: $244 · 2024: $343 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,319.36 | 2019-2023 | Mavyret |
| Gilead Sciences, INC. | $799.71 | 2019-2023 | Epclusa, Vemlidy |
| Janssen Biotech, INC. | $374.42 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.98 | 2019-2021 | |
| Boston Scientific Corporation | $309.19 | 2019-2025 | Resolution 360 Clip, Exalt Model D, Lithovue |
| Madrigal Pharmaceuticals | $308.61 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $278.43 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $223.14 | 2019-2021 | |
| Lilly USA, LLC | $163.13 | 2025 | Omvoh |
| Olympus America INC. | $142.55 | 2019-2024 | Olympus |
| Phathom Pharmaceuticals, INC. | $134.00 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $120.41 | 2025 | Ibsrela |
| Celgene Corporation | $100.90 | 2021 | |
| Intercept Pharmaceuticals, INC. | $97.81 | 2019-2021 | |
| Haemonetics Corporation | $97.71 | 2024 | Teg6s Hemostasis System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $75.09 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $46.70 | 2020 | |
| Nestle Healthcare Nutrition INC. | $38.31 | 2021 | |
| Allergan, INC. | $29.35 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $18.19 | 2019 | |
| Pfizer INC. | $15.31 | 2019 | |
| Shire North American Group INC | $12.93 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $12.33 | 2024 | Eyemax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavin Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.